Decision: Favourable
Study Title:
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)
NREC Code:
22-NREC-CT-029
Decision:
Favourable
Meeting Date:
23/02/2022
Study Type:
CT application
Principal Investigator:
Dr. Karen Cadoo
PI Institution:
St James's Hospital
Sponsor:
MSD